双鹭药业上市公司投资者关系活动记录表 证 券 代 | --- | --- | --- | |----------------------------|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------| | 码： | □特定对象调研 | 证券简称：双鹭药业编号： □分析师会议 | | | □媒体采访 □ | 业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □ | 路演活动 | | | □现场参观 | 电话会议 | | | □ | | | 参与单及人员姓名 | 其他：（请文字说明其他活动内容）东吴证券代表参与此次电话会议 | 中信期货、淡水泉投资、嘉实、东方自营、上海翀云私募基金、途灵资产、汇华理财、南土资产、太平资产、乾璐投资、中信建投自营等机构 | | 位名时间 | 联席年月 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥583,506,665.49, representing a 5.29% increase compared to ¥554,215,134.55 in the same period last year[21]. - Net profit attributable to shareholders increased by 91.84% to ¥317,164,126.27 from ¥165,327,395.95 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥194,176,556.41, up 37.28% from ¥141,441,380.82 in the previous year[21]. - Basic and diluted earnings per share rose by 93.75% to ¥0.31 from ¥0.16 in the same period last year[21]. - The net cash flow from operating activities was ¥190,252,963.39, an increase of 8.31% compared to ¥175,663,138.41 in the previous year[21]. - Total assets at the end of the reporting period reached ¥6,086,827,335.16, a 3.59% increase from ¥5,875,839,869.74 at the end of the previous year[21]. - Net assets attributable to shareholders increased by 3.92% to ¥5,682,511,453.93 from ¥5,468,082,327.66 at the end of the previous year[21]. - The weighted average return on net assets improved to 5.64%, up from 3.06% in the previous year[21]. Research and Development - The company focuses on gene engineering and related drug research and production, with eight major production bases covering various dosage forms and therapeutic areas[29]. - In the first half of 2023, the company obtained drug registration certificates for five products, including Voglibose tablets and Dapagliflozin tablets[30]. - The company employs a combination of self-research, technical cooperation, and project investment for its R&D efforts, with several products currently under review for market approval[31]. - Research and development investment rose by 31.01% to ¥182.94 million, driven by an increase in clinical research projects[38]. - The company aims to improve its international market competitiveness through the launch of new gene-engineered drugs and specialty medicines[34]. Market Strategy and Operations - The company is focusing on expanding its market share by enhancing its marketing strategies and developing grassroots medical institutions[34]. - The production model is based on "sales-driven production," ensuring product quality and safety through strict regulatory compliance[32]. - The company plans to increase the proportion of innovative drug development and services while expanding into the industrial hemp sector and healthcare investments[30]. - The company has established a unified procurement department to ensure timely supply of raw materials based on production plans and market conditions[38]. Financial Position and Assets - The company's financial assets totaled 795,949,417.80 yuan at the end of the reporting period, with a net increase of 108,112,364.36 yuan[46]. - The company has judicially frozen assets amounting to 135,956,895.39 yuan due to an ongoing arbitration with Nanjing Cavendish Biotechnology[47]. - The total assets of the subsidiary Beijing Shuanglu Biotechnology Co., Ltd. were 348,357,660 yuan, with a net profit of 24,845,235 yuan[55]. - Current assets increased to CNY 2,039,044,474.34 as of June 30, 2023, up from CNY 1,997,673,975.30 at the beginning of the year, representing a growth of approximately 2.0%[123]. - Total non-current assets reached CNY 4,047,782,860.82, up from CNY 3,878,165,894.44, indicating an increase of about 4.4%[124]. Legal and Compliance Issues - The company is involved in arbitration with Nanjing Cavendish Bioengineering Co., Ltd. regarding the "ornidazole injection project," claiming a payment of 70% of the unpaid amount, which totals approximately ¥11.58 million[83]. - The company has filed multiple lawsuits against Nanjing Cavendish for serious breaches of technology transfer contracts, with claims including a request for the return of approximately ¥1.31 million and a penalty of ¥5 million[84]. - There were no significant litigation or arbitration matters reported during the period[82]. - The company has no significant related party transactions or major contracts during the reporting period[88][89][95]. Environmental and Social Responsibility - The company has established comprehensive wastewater and air pollution treatment facilities, ensuring stable operation of monitoring systems[70]. - The company actively fulfilled its social responsibilities by providing poverty alleviation subsidies to families affected by serious illnesses and donating medical equipment to elderly hospitals[75]. - The company has prepared an emergency response plan for environmental incidents, which has been filed with the local environmental protection bureau[71]. Shareholder Information - The total number of shares before the change was 1,027,350,000, with 17.13% being limited shares and 82.87% being unrestricted shares[105]. - The largest shareholder, Xu Mingbo, holds 232,406,307 shares, representing 22.62% of the total shares[110]. - The total number of shareholders at the end of the reporting period was 53,082[109]. - The company has a policy that limits the transfer of shares for departing executives for six months[107]. Future Outlook - Future plans and forward-looking statements are included in the report, emphasizing the importance of investor caution regarding potential risks[4]. - The company plans to continue focusing on research and development of new products and technologies to drive future growth[136]. - The company aims to build a complete ecosystem in the pharmaceutical health sector to achieve long-term stable growth[30].

单位：万元 | 非经营性资金占 | | | 占用方与上市公司的 | 上市公司核 | 2023 年期 2023 | 年半年度占 | 2023 | 年半年度 | 2023 | 年半年 | 2023 年半年 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 用 | 资金占用方名称 | | 关联关系 | 算的会计科 | 初占用资 | 用累计发生金额 | | 占用资金的利 | | 度偿还累计 | 度期末占用 | 原因 | | | | | | | 目 | 金余额 | （不含利息） | | 息（如有） | | 发生金额 | 资金余额 | | | | 控股股东、实际控 制人及其附属企业 | | | | | | | | | | | | | 非经营性占用 | | 小计 | | - | - | - | | | | | | | | | - | | 前控股股东、实际 控制人及其附属企 | | | | | | | | | | | | | 非经营性占用 | | 业 小计 | | - ...

北京双鹭药业股份有限公司独立董事 关于控股股东及其他关联方占用公司资金、公司对外担保情况的 专项说明和独立意见 为保护北京双鹭药业股份有限公司（以下简称"公司"）全体股东的利益，根据中国证 监会《上市公司独立董事规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》及《公司章程》等有关规定，作为公司的独立董事，在审阅相关资料 后，发表独立意见如下： 根据中国证监会证监发[2022]第 26 号公告《上市公司监管指引第 8 号——上市公司资 金往来、对外担保的监管要求》对上市公司的规定和要求，我们作为北京双鹭药业股份有 限公司的独立董事，本着对公司、全体股东及投资者负责的态度，按照实事求是的原则对 公司截止 2023 年 6 月 30 日对外担保情况和控股股东及其他关联方占用资金情况进行了认 真负责的核查，认为： 1、公司能严格遵循《公司法》、《证券法》、《上市公司监管指引第 8 号——上市公司资 金往来、对外担保的监管要求》等法律法规和《公司章程》、《对外担保管理办法》、《规范 与关联方资金往来管理制度》、《关联交易管理制度》的有关规定。 2、至本报告期末，公司累积和当期无任何形式 ...

一、 董事会会议召开情况 北京双鹭药业股份有限公司（以下简称"公司"）第八届董事会第九次会议于 2023 年 8 月 24 日以现场结合通讯方式在公司总部会议室（北京海淀区碧桐园一号楼四层）召开，会议通知 于 2023 年 8 月 11 日以通讯方式送达。本次会议由董事长徐明波先生主持，会议应出席董事 6 名，实际出席董事 6 名，公司全体监事及高级管理人员列席了本次会议。本次会议的召集、召 开符合《公司法》、《公司章程》和《董事会议事规则》的有关规定。 二、董事会会议审议情况 证券代码：002038 证券简称：双鹭药业 公告编号：2023-029 北京双鹭药业股份有限公司 第八届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 议案表决情况：本议案有效表决票 6 票，同意 6 票，反对 0 票，弃权 0 票。 三、备查文件 经与会董事签字并加盖公司公章的董事会决议。 特此公告。 北京双鹭药业股份有限公司董事会 二〇二三年八月二十五日 经与会董事审议并表决了以下议案： （一）审议通过了《2023 年半年度报告》及《2023 年半年度报告 ...

本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 一、监事会会议召开情况 北京双鹭药业股份有限公司（以下简称"公司"）第八届监事会第九次会议于 2023 年 8 月 24 日以现场结合通讯方式在公司总部会议室（北京海淀区碧桐园一号楼四层）召开，会议通知于 2023 年 8 月 11 日以通讯方式送达。本次会议由公司监事会主席齐燕明女士主持，会议应出席监事 3 名，实际出席监事 3 名。本次会议的召集、召开符合《公司法》、《公司章程》和《监事会议事规 则》的有关规定。 二、审议事项 证券代码：002038 证券简称：双鹭药业 公告编号：2023-030 第八届监事会第九次会议决议公告 北京双鹭药业股份有限公司 （一）审议通过了《2023 年半年度报告》及《2023 年半年度报告摘要》 经审核，监事会认为董事会编制和审核北京双鹭药业股份有限公司《2023 年半年度报告》及 《2023 年半年度报告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准 确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 议案内容详见公司于 2 ...

证券代码：002038 证券简称：双鹭药业 双鹭药业上市公司投资者关系活动记录表 编号：2023-002 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 类别 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他： （请文字说明其他活动内容） | --- | --- | |--------------|------------------------------------------------------------------| | 参与单位名称 | 东海证券、东吴证券、合易盈通、国中长城、开熙投资、舜乾投资等机 | | 及人员姓名 | 构投资者、行业分析师以及财经媒体同花顺、上市公司网等，共计23人。 | 时间 2023 年 5 月 26 日下午 14：00-16：30 地点 双鹭药业会议室 公司接待人员 姓名 公司董事长、总经理徐明波先生，董事、董事会秘书梁淑洁女士 首先梁淑洁女士介绍了公司基本情况，公司发展历史、公司目前的 生产布局、在研重点项目和研发队伍情况，公司上市产品的竞争情况， 公司主要产品最近几年的销售情况，集采政策推出后公司进入集采的产 品的市场变化，目前在 ...

证券代码： 002038 证券简称：双鹭药业 2、 梁董好！公司的紫杉醇胶束工艺放大进展怎么样，什么时候 能重新进入临床？长效 EPO、GIP/GLP1-Fc、ADCC 增强型曲妥珠、ADCC 增强型西妥昔和 DT-109 这些品种什么时候能申报临床呢？其中有哪 些品种已经申报临床前沟通交流会了？与 ATGC 公司合作开发的药品 什么时候能有申报临床品种呢？ 紫杉醇胶束工艺放大正在优化；长效 EPO 目前正在展开临床前质 量提升与稳定性研究和药理、药代毒理试验；GIP/GLP1-Fc 目前已完 成药性评价，已建立小试工艺；ADCC 增强型曲妥珠目前正展开临床前 质量与稳定性研究，正在进行药理毒理试验；ADCC 增强型西妥昔正在 进行细胞培养基与层析填料国产化替代后的制备工艺中试放大；DT- 109 在临床前药理毒理评价。这些项目申报临床尚需 1-3 年。谢谢关 注。 3、 从 22 年年报中的董事、监事、高级管理人员来看，年纪都 在 50 岁开外，唯一一个 40 多岁的高管又已经辞职，通常 50 岁以后 稳健有余进取不足，可能这也是近些年业绩一直徘徊 12 亿左右的一 个原因。深市互动易股民多次提出加强销售， ...

北京双鹭药业股份有限公司 2023 年第一季度报告 证券代码：002038 证券简称：双鹭药业 公告编号：2023-0011 北京双鹭药业股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第一季度报告是否经审计 □是 否 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 296,576,777.05 | 274,551,424.02 | 8.02% | | 归属于上市公司股东的净利 | 201,929,706.82 | 63,295,907.68 | 219.02% | | 润（ ...

Product Portfolio and Therapeutic Areas - The company's main products include recombinant human granulocyte colony-stimulating factor injection (rhG-CSF), recombinant human interleukin-11 for injection (rhIL-11), and recombinant human interleukin-2 injection (125Ala IL-2), which are used for treating conditions such as neutropenia caused by chemotherapy, thrombocytopenia, and various cancers[22] - The company's product portfolio spans multiple therapeutic areas including oncology, cardiovascular, endocrine, liver disease, and kidney disease, with products like Temozolomide Capsules for glioblastoma and Lenalidomide Capsules for multiple myeloma[22] - The company's product "Fuji Fu" (recombinant human basic fibroblast growth factor gel) is used for wound healing and has received multiple national awards and recognitions[22] - The company's product "Xin Er Jin" (Paclitaxel Injection) is used for the treatment of ovarian cancer, breast cancer, and non-small cell lung cancer, and is currently under consistency evaluation[22] - The company's product "Yi Yuan" (Docetaxel Injection) has passed consistency evaluation and is used for advanced or metastatic breast cancer and non-small cell lung cancer[22] - The company's product "Li Yi" (Asparaginase for Injection) is used for the treatment of various leukemias, lymphomas, and melanomas[22] - The company's product "Gu Lin" (Calcium Folinate for Injection) is used for the treatment of advanced colorectal cancer and megaloblastic anemia[22] - The company's product "Dun Ning" (Ornidazole Injection) is used for the treatment of various anaerobic infections and has passed consistency evaluation[22] - The company's product "Xin Fu Nuo" (Adefovir Dipivoxil Capsules) is used for the treatment of chronic hepatitis B and has received multiple awards and recognitions[22] - The company's product portfolio includes antiviral drugs such as Xinfusai® Ribavirin Tablets and Lishengwei® Valacyclovir Hydrochloride Tablets, which are used for treating viral pneumonia, bronchitis, and herpes infections[23] - Lishengwei® Valacyclovir Hydrochloride Tablets are specifically indicated for the treatment of varicella-zoster and herpes simplex virus infections, including genital herpes[23] - Lishengwei® Tenofovir Disoproxil Fumarate Tablets are approved for chronic hepatitis B and HIV-1 infections in adults and children aged 12 and above, having passed consistency evaluation[23] - Lishengwei® Oseltamivir Phosphate Capsules are used for the prevention and treatment of influenza A and B, also having passed consistency evaluation[23] - The company has a strong focus on organ transplant medications, such as Lishengping® Cyclosporine Injection and Capsules, which are used to prevent rejection post-transplant[23] - The company's product line also includes cardiovascular drugs like Limai® Xingling Dropping Pills and Xinyier® Telmisartan Tablets/Capsules, with the latter having applied for consistency evaluation[23] - In the diabetes treatment segment, Lishengtai® Voglibose Tablets and Lishengheng® Dapagliflozin Tablets have passed consistency evaluation and are used for managing postprandial hyperglycemia and type 2 diabetes, respectively[23] Production and Manufacturing - The company has multiple production bases in Beijing and Hebei, producing a wide range of pharmaceutical forms including tablets, capsules, injections, and biological products[21] - The acquisition of Xinxiang Shuanglu Pharmaceutical as a wholly-owned subsidiary will expand investment scale and increase the scope of formulation production, addressing the high-cost disadvantage of the Beijing production base and enhancing product profitability[110] - The company will continue to strengthen its production quality system and enhance drug safety and effectiveness control[132] Research and Development - The company leverages its robust biotechnological platform to develop innovative biochemical drugs, with significant progress in research and industrialization of products like adenosylmethionine and enoxaparin sodium[30] - The company's founder and chairman, Dr. Xu Mingbo, has led the team to achieve multiple scientific research awards and has been instrumental in the development and commercialization of several gene-engineered drugs[31] - The company's first-generation gene engineering pharmaceutical products have entered the harvest period, with more than a dozen important products at different stages of development[33] - Two second-generation gene engineering blockbuster new products are expected to be launched within the next two years, significantly enhancing the company's competitiveness in biologics[33] - The company's anti-platelet drug for acute coronary syndrome has completed Phase I clinical trials, showing strong competitiveness and potential[34] - Key biologic projects such as FSH-CTP completed Phase II clinical trials, and several chemical drug projects have submitted registration applications or completed consistency evaluation[37] - The company plans to submit the SL201 project for market registration in 2023 and initiate phase III clinical studies for SL202, SL209, and SL222 projects[130] - The company aims to accelerate the launch of new products and increase R&D investment in innovative drugs to enhance competitiveness[134] Sales and Market Performance - The company's top-selling product, Temozolomide capsules, accounted for 24.63% of total sales revenue, while human granulocyte colony-stimulating factor accounted for 12.52%[49] - Sales volume of biological and biochemical drugs increased by 2.52% year-over-year, with production volume up by 3.64%[57] - Inventory of biological and biochemical drugs increased by 14.18%, while chemical drug inventory decreased by 20.68%[57] - The top five customers accounted for 11.72% of total annual sales, with the largest customer contributing 2.75%[60] - The company successfully renewed the bid for Temozolomide and won bids for Argatroban and Ornidazole in the eighth national centralized procurement[48] - Oseltamivir phosphate was approved for market launch and performed well during the 2023 flu season[53] Corporate Strategy and Management - The company will continue to strengthen market promotion for key products, increase investment in internet marketing, and enhance performance management for marketing personnel to boost their motivation and loyalty[111] - The company will focus on talent development and incentive mechanisms, improving the reward and punishment system, and implementing competitive recruitment and performance evaluations to increase employee compensation and benefits[111] - The company will continue to cultivate and introduce mid-to-high-end technical and management talents, and promote the implementation of technical and skill talent training programs and project reward systems[111] - The company will actively fulfill its social responsibilities by regularly donating free treatment drugs to disadvantaged groups and providing emergency medical supplies during public health crises[111] - The company is focusing on developing innovative drugs and differentiated marketing strategies to avoid the impact of centralized procurement and enhance product competitiveness[115] - The company will strengthen project management efficiency and improve R&D success rates to mitigate risks associated with the long development cycles and high investment in biopharmaceuticals[115] - The company will continue to update and cultivate management talent to ensure that management philosophies keep pace with the company's growth and industry developments[115] Financial Performance - Beijing Shuanglu Lisheng Pharmaceutical Technology Co., Ltd. achieved a net profit of 26.55 million yuan, with a total revenue of 62.50 million yuan[126] - Beijing Shuanglu Biotechnology Co., Ltd. reported a net loss of 6.59 million yuan, with a total revenue of 46.82 million yuan[126] - Xinxiang Shuanglu Pharmaceutical Co., Ltd. recorded a net loss of 617,284.69 yuan, with a total revenue of 12.48 million yuan[126] - Liaoning Maidi Biotechnology Co., Ltd. reported a net loss of 2.80 million yuan, with a total revenue of 7.23 million yuan[126] - Haibu Biotechnology (Yunnan) Co., Ltd. recorded a net loss of 967,823.61 yuan, with a total revenue of 32,538.56 yuan[126] Market Challenges and Risks - The 8th batch of national centralized procurement in 2023 included 41 drug varieties and 181 specifications, with prices expected to drop significantly, intensifying competition in the generic drug market[114] - The company faces risks from the ongoing national centralized procurement, which may lead to price reductions and compressed profit margins, particularly for products with large market shares[115] - The company will face challenges from national and provincial centralized drug procurement, which may reduce profit margins for some products[135] Acquisitions and Subsidiaries - The company has completed the acquisition of a 30% stake in Xinxiang Shuanglu Pharmaceutical Co., Ltd., making it a wholly-owned subsidiary[128]